Cargando…

Efficacy and Safety of Neoadjuvant Targeted Therapy vs. Neoadjuvant Chemotherapy for Stage IIIA EGFR-Mutant Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Purpose: The role of targeted therapy in the neoadjuvant field of stage IIIA epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) is still controversial. We sought to evaluate the efficacy and safety of neoadjuvant targeted therapy (NTT) with neoadjuvant chemo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Dong, Jin, Zixian, Zhang, Jian, Xu, Congcong, Zhu, Kanghao, Ruan, Yuhang, Zhang, Bo, Chen, Baofu, Shen, Jianfei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Surgery
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8417411/ https://www.ncbi.nlm.nih.gov/pubmed/34490338 http://dx.doi.org/10.3389/fsurg.2021.715318

Ejemplares similares

Efficacy and Benefit of Postoperative Chemotherapy in Micropapillray or Solid Predominant Pattern in Stage IB Lung Adenocarcinoma: A Systematic Review and Meta-Analysis
por: Xu, Congcong, et al.
Publicado: (2021)

Efficacy and safety of immune checkpoint inhibitors versus chemotherapy in the second-line treatment of advanced esophageal squamous cell carcinoma: a meta-analysis and systematic review
por: Zhu, Kanghao, et al.
Publicado: (2023)

Neoadjuvant Immuno-Chemotherapy: A New Perspective for Stage III NSCLC?
por: Yao, Yuanshan, et al.
Publicado: (2022)

Neoadjuvant treatment of stage IIIA-N2 in EGFR-Mutant/ALK-rearranged non-small cell lung cancer
por: Reyes, Roxana, et al.
Publicado: (2021)

Neoadjuvant osimertinib and chemotherapy for stage IIIA primary pulmonary carcinosarcoma with EGFR 19DEL mutation: A case report
por: Wang, Hongming, et al.
Publicado: (2023)

Safety and Feasibility of Esophagectomy Following Neoadjuvant Immunotherapy Combined with Chemotherapy for Esophageal Squamous Cell Carcinoma
por: Gu, Yi-Min, et al.
Publicado: (2022)

Minimally invasive versus open esophagectomy after neoadjuvant therapy for esophageal cancer: a meta-analysis
por: Jin, Zixian, et al.
Publicado: (2023)

Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer
por: Chen, Yulong, et al.
Publicado: (2021)

Clinical significance and prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients
por: He, Yang, et al.
Publicado: (2023)

Case Report: Pathologic Complete Response to Pembrolizumab in Combination With Neoadjuvant Chemotherapy in a Patient With Stage IIB Squamous Lung Cancer
por: Zhang, Lin, et al.
Publicado: (2020)

Perioperative safety and feasibility outcomes of stage IIIA-N2 non-small cell lung cancer following neoadjuvant immunotherapy or neoadjuvant chemotherapy: a retrospective study
por: Huang, Zhangfeng, et al.
Publicado: (2021)

Efficacy and safety of vinorelbine and cisplatin regimen of different doses and intensities for neoadjuvant chemotherapy in patients with locally advanced esophageal carcinoma
por: Jin, Ke, et al.
Publicado: (2021)

Prognostic value of final pathological stage in colon adenocarcinoma after neoadjuvant chemotherapy: A propensity score-matched study
por: Xiang, Meijuan, et al.
Publicado: (2022)

Novel peripheral blood parameters as predictors of neoadjuvant chemotherapy response in breast cancer
por: Yang, Gaohua, et al.
Publicado: (2022)

Immediate Breast Reconstruction After Neoadjuvant Chemotherapy: Factors Associated With Surgical Selection and Complications
por: Chi, Weiru, et al.
Publicado: (2023)

Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases
por: Li, Xin, et al.
Publicado: (2022)

The prognostic role of lymph node ratio in breast cancer patients received neoadjuvant chemotherapy: A dose-response meta-analysis
por: Liu, Jinzhao, et al.
Publicado: (2022)

A single-arm, multicenter, phase II clinical study of tislelizumab plus albumin-bound paclitaxel/cisplatin as neoadjuvant therapy for borderline resectable esophageal squamous cell carcinoma
por: Li, Xiaodong, et al.
Publicado: (2022)

Interval time between neoadjuvant chemotherapy and surgery in advanced gastric cancer doesn't affect outcome: A meta analysis
por: Zhai, Yuhao, et al.
Publicado: (2023)

Efficacy and outcome analysis: Combination of Endostar and chemotherapy as a neoadjuvant treatment of stage IIIA/IIIB squamous cell lung cancer
por: Cao, Feiyi, et al.
Publicado: (2023)

Effect of preoperative radiotherapy on the prognosis of patients with stage cTxN0M0 esophageal squamous cell carcinoma: propensity score matching analysis based on SEER database
por: Jin, Zixian, et al.
Publicado: (2023)

Prospective Evaluation of Response Outcomes of Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer
por: A., Ashok, et al.
Publicado: (2022)

Short-Course or Total Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer - Current Status and Future Perspectives
por: Labori, Knut Jørgen
Publicado: (2022)

Single-cell profiling of immune cells after neoadjuvant pembrolizumab and chemotherapy in IIIA non-small cell lung cancer (NSCLC)
por: Hui, Zhenzhen, et al.
Publicado: (2022)

Laparoscopic or open distal gastrectomy after neoadjuvant chemotherapy for advanced gastric cancer: study protocol for a randomised phase II trial
por: Li, Ziyu, et al.
Publicado: (2018)

Development and Validation of a Nomogram to Predict the Probability of Breast Cancer Pathologic Complete Response after Neoadjuvant Chemotherapy: A Retrospective Cohort Study
por: Li, Yijun, et al.
Publicado: (2022)

Decrease in Blood Neutrophil-to-Lymphocyte Ratio Indicates Better Survival After Neoadjuvant Chemotherapy in Patients With Advanced Gastric Cancer
por: Liu, Ziyi, et al.
Publicado: (2021)

Neoadjuvant Bevacizumab Plus Docetaxel/Cisplatin/Capecitabine Chemotherapy in Locally Advanced Gastric Cancer Patients: A Pilot Study
por: Yu, Deguo, et al.
Publicado: (2022)

The safety and efficacy of neoadjuvant programmed death 1 inhibitor therapy with surgical resection in stage IIIA non-small cell lung cancer
por: Wang, Jiangfeng, et al.
Publicado: (2021)

Osimertinib as neoadjuvant therapy in a patient with stage IIIA non-small cell lung cancer: a case report
por: Chen, Caroline Y., et al.
Publicado: (2021)

Editorial: Frontiers' research topic “advances in esophageal cancer surgery with neoadjuvant therapies”
por: Shang, Qi-Xin, et al.
Publicado: (2023)

Association of serum reproductive hormones changes after neoadjuvant chemotherapy with hormone receptors expression alterations and survival outcomes in breast cancer
por: Lan, Ailin, et al.
Publicado: (2022)

Surgery or Non-surgical Treatment of ≤8 mm Non-small Cell Lung Cancer: A Population-Based Study
por: Shen, Jianfei, et al.
Publicado: (2021)

Neoadjuvant chemoradiotherapy with camrelizumab in patients with locally advanced esophageal squamous cell carcinoma
por: Chen, Fei, et al.
Publicado: (2022)

Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLC
por: Brazel, Danielle, et al.
Publicado: (2022)

Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial
por: Zhong, Wen-Zhao, et al.
Publicado: (2023)

Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study
por: Bian, Dongliang, et al.
Publicado: (2023)

Comparison of Four Lymph Node Staging Systems in Gastric Adenocarcinoma after Neoadjuvant Therapy – A Population-Based Study
por: Lai, Hongkun, et al.
Publicado: (2022)

Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation‐Positive Non‐Small Cell Lung Cancer: A Prospective, Single‐Arm, Phase II Study
por: Xiong, Liwen, et al.
Publicado: (2018)

Neoadjuvant chemoimmunotherapy as a potential therapeutic option in NSCLC UICC stage IIIA with multilevel N2 disease
por: Menghesha, Hruy, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rmfh16q6ha0ftpkf1mvs3ne1qh